The invention relates to the use of eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid in the manufacture of a medicament for reducing a risk of a cardiovascular event selected from the group consisting of cardiovascular death, coronary revascularization, and/or unstable angina in a subject on stable statin therapy, wherein: (a) the subject has previously been identified as having dyslipidemia, as being on stable statin therapy and as having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, optionally wherein said subject has established cardiovascular disease or has a high risk of developing cardiovascular disease； and (b) the medicament is formulated for daily administration to provide about 4 g of the eicosapentaenoic acid per day. The invention also relates to the use of eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid in the manufacture of a medicament for reducing a risk of a cardiovascular event in a subject on statin therapy (a) with residual atherogenic dyslipidemia and clinically evident cardiovascular disease or (b) without clinically evident cardiovascular disease but with increased risk of cardiovascular disease, wherein: (a) the medicament is formulated for daily administration for a period of at least about 2 years of about 4g of eicosapentaenoic acid； and (b) the use reduces risk of cardiovascular disease, need for coronary revascularization, risk of unstable angina, risk for stroke, risk for myocardial infarction, or any combination thereof.
